Literature DB >> 11050138

Interleukin-1beta -induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study.

A M Blamire1, D C Anthony, B Rajagopalan, N R Sibson, V H Perry, P Styles.   

Abstract

The cytokine interleukin-1beta (IL-1beta) is implicated in a broad spectrum of CNS pathologies, in which it is thought to exacerbate neuronal loss. Here, the effects of injecting recombinant rat IL-1beta into the striatum of 3-week-old rats were followed noninvasively from 2 to 123 hr using magnetic resonance imaging and spectroscopy. Four hours after injection of IL-1beta (1 ng in 1 microliter), cerebral blood volume was significantly increased, the blood-brain barrier (BBB) became permeable to intravenously administered contrast agent between 4.5 and 5 hr, and the apparent diffusion coefficient (ADC) of brain water fell by 6 hr (5.42 +/- 0. 35 x 10(-4) mm(2)/sec treated, 7.35 +/- 0.77 x 10(-)(4) mm(2)/sec control; p < 0.001). At 24 hr the BBB was again intact, but the ADC, although partially recovered, remained depressed at both 24 and 123 hr (p < 0.03). Depleting the animals of neutrophils before IL-1beta injection prevented the BBB permeability at all time points, but the ADC was still depressed at 6 hr (6.64 +/- 0.34 x 10(-4) mm(2)/sec treated, 7.49 +/- 0.38 x 10(-4) mm(2)/sec control; p < 0.005). No changes were seen in brain metabolites using proton spectroscopy at 6 hr after IL-1beta. Intraparenchymal injection of IL-1beta caused a neutrophil-dependent transient increase in BBB permeability. The presence of neutrophils within the brain parenchyma significantly contributed to the IL-1beta-induced changes in cerebral blood volume and the ADC of brain water. However, IL-1beta apparently had a direct effect on the resident cell populations, which persisted well after all recruited leukocytes had disappeared. Thus the action of IL-1beta alone can give rise to magnetic resonance imaging-visible changes that are normally attributed to alterations to cellular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050138      PMCID: PMC6772751     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

Authors:  S L Hauser; T H Doolittle; R Lincoln; R H Brown; C A Dinarello
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

2.  Echo-planar imaging of intravoxel incoherent motion.

Authors:  R Turner; D Le Bihan; J Maier; R Vavrek; L K Hedges; J Pekar
Journal:  Radiology       Date:  1990-11       Impact factor: 11.105

3.  Dynamic changes in water ADC, energy metabolism, extracellular space volume, and tortuosity in neonatal rat brain during global ischemia.

Authors:  A van der Toorn; E Syková; R M Dijkhuizen; I Vorísek; L Vargová; E Skobisová; M van Lookeren Campagne; T Reese; K Nicolay
Journal:  Magn Reson Med       Date:  1996-07       Impact factor: 4.668

4.  TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier.

Authors:  M Fiala; D J Looney; M Stins; D D Way; L Zhang; X Gan; F Chiappelli; E S Schweitzer; P Shapshak; M Weinand; M C Graves; M Witte; K S Kim
Journal:  Mol Med       Date:  1997-08       Impact factor: 6.354

5.  Temporal evolution of ischemic damage in rat brain measured by proton nuclear magnetic resonance imaging.

Authors:  R A Knight; R J Ordidge; J A Helpern; M Chopp; L C Rodolosi; D Peck
Journal:  Stroke       Date:  1991-06       Impact factor: 7.914

6.  Monitoring the initial expansion of focal ischaemic changes by diffusion-weighted MRI using a remote controlled method of occlusion.

Authors:  S A Roussel; N van Bruggen; M D King; J Houseman; S R Williams; D G Gadian
Journal:  NMR Biomed       Date:  1994-03       Impact factor: 4.044

7.  Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage.

Authors:  H Hara; R M Friedlander; V Gagliardini; C Ayata; K Fink; Z Huang; M Shimizu-Sasamata; J Yuan; M A Moskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

8.  Comparison of MR perfusion imaging and microsphere measurements of regional cerebral blood flow in a rat model of middle cerebral artery occlusion.

Authors:  T B Müller; R A Jones; O Haraldseth; J Westby; G Unsgård
Journal:  Magn Reson Imaging       Date:  1996       Impact factor: 2.546

Review 9.  The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications.

Authors:  N Rothwell; S Allan; S Toulmond
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

10.  Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats.

Authors:  D C Anthony; S J Bolton; S Fearn; V H Perry
Journal:  Brain       Date:  1997-03       Impact factor: 13.501

View more
  86 in total

Review 1.  Innate immunity in the central nervous system.

Authors:  Richard M Ransohoff; Melissa A Brown
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

2.  CD8 T cell-initiated blood-brain barrier disruption is independent of neutrophil support.

Authors:  Holly L Johnson; Yi Chen; Fang Jin; Lisa M Hanson; Jeffrey D Gamez; Istvan Pirko; Aaron J Johnson
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

3.  Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease.

Authors:  Yuling Zhao; Matthew J Haney; Vivek Mahajan; Benjamin C Reiner; Anna Dunaevsky; R Lee Mosley; Alexander V Kabanov; Howard E Gendelman; Elena V Batrakova
Journal:  J Nanomed Nanotechnol       Date:  2011-09-10

4.  Macrophages with cellular backpacks for targeted drug delivery to the brain.

Authors:  Natalia L Klyachko; Roberta Polak; Matthew J Haney; Yuling Zhao; Reginaldo J Gomes Neto; Michael C Hill; Alexander V Kabanov; Robert E Cohen; Michael F Rubner; Elena V Batrakova
Journal:  Biomaterials       Date:  2017-06-18       Impact factor: 12.479

Review 5.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 6.  Blood-brain barrier dysfunction and recovery.

Authors:  A G de Boer; P J Gaillard
Journal:  J Neural Transm (Vienna)       Date:  2006-04       Impact factor: 3.575

7.  Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease.

Authors:  Sander I van Kasteren; Sandra J Campbell; Sébastien Serres; Daniel C Anthony; Nicola R Sibson; Benjamin G Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

8.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

9.  Non-muscle Mlck is required for β-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1β-mediated barrier dysfunction in brain endothelial cells.

Authors:  Richard S Beard; Ricci J Haines; Kevin Y Wu; Jason J Reynolds; Stephanie M Davis; John E Elliott; Nikolay L Malinin; Victor Chatterjee; Byeong J Cha; Mack H Wu; Sarah Y Yuan
Journal:  J Cell Sci       Date:  2014-02-12       Impact factor: 5.285

10.  Change in blood-brain barrier permeability during pediatric diabetic ketoacidosis treatment.

Authors:  Monica S Vavilala; Todd L Richards; Joan S Roberts; Harvey Chiu; Catherine Pihoker; Heidi Bradford; Kristina Deeter; Ken I Marro; Dennis Shaw
Journal:  Pediatr Crit Care Med       Date:  2010-05       Impact factor: 3.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.